Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.

Neuhausen SL, Ozcelik H, Southey MC, John EM, Godwin AK, Chung W, Iriondo-Perez J, Miron A, Santella RM, Whittemore A, Andrulis IL, Buys SS, Daly MB, Hopper JL, Seminara D, Senie RT, Terry MB; Breast Cancer Family Registry.

Breast Cancer Res Treat. 2009 Jul;116(2):379-86. doi: 10.1007/s10549-008-0153-8. Epub 2008 Aug 14.

2.

Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.

Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, Rennert G.

Ann Oncol. 2011 Apr;22(4):964-6. doi: 10.1093/annonc/mdq460. Epub 2010 Oct 5.

3.

Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis.

Takano EA, Mitchell G, Fox SB, Dobrovic A.

BMC Cancer. 2008 Feb 25;8:59. doi: 10.1186/1471-2407-8-59.

4.

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.

Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME.

Cancer. 2012 Jan 15;118(2):493-9. doi: 10.1002/cncr.26191. Epub 2011 May 19.

5.

Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.

Hedau S, Jain N, Husain SA, Mandal AK, Ray G, Shahid M, Kant R, Gupta V, Shukla NK, Deo SS, Das BC.

Breast Cancer Res Treat. 2004 Nov;88(2):177-86.

PMID:
15564800
6.

Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.

Goodwin PJ, Phillips KA, West DW, Ennis M, Hopper JL, John EM, O'Malley FP, Milne RL, Andrulis IL, Friedlander ML, Southey MC, Apicella C, Giles GG, Longacre TA.

J Clin Oncol. 2012 Jan 1;30(1):19-26. doi: 10.1200/JCO.2010.33.0068. Epub 2011 Dec 5.

PMID:
22147742
7.

Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.

Cierniková S, Tomka M, Kovác M, Stevurková V, Zajac V.

Neoplasma. 2006;53(2):97-102.

PMID:
16575464
8.

BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.

Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB.

J Natl Cancer Inst. 2004 Jan 7;96(1):15-21.

PMID:
14709734
9.

The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.

Gal I, Gershoni Baruch R, Haber D, Dagan E, Eisenberg-Barzilai S, Zidan J, Friedman E.

Fam Cancer. 2004;3(1):11-4.

PMID:
15131400
10.

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.

Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC.

J Clin Oncol. 2002 Mar 15;20(6):1480-90.

PMID:
11896095
11.

The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.

Palma MD, Domchek SM, Stopfer J, Erlichman J, Siegfried JD, Tigges-Cardwell J, Mason BA, Rebbeck TR, Nathanson KL.

Cancer Res. 2008 Sep 1;68(17):7006-14. doi: 10.1158/0008-5472.CAN-08-0599. Epub 2008 Aug 14.

12.

Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.

Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, Narod SA.

N Engl J Med. 2007 Jul 12;357(2):115-23.

13.

The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.

Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA.

Am J Hum Genet. 1999 Apr;64(4):963-70.

14.

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.

Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E.

Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14205-10. doi: 10.1073/pnas.1415979111. Epub 2014 Sep 5.

15.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

16.

Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Casey MJ, Bewtra C.

Fam Cancer. 2004;3(3-4):265-81. Review.

PMID:
15516851
17.
18.

Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer.

Gershoni-Baruch R, Dagan E, Fried G, Bruchim Bar-Sade R, Sverdlov-Shiri R, Zelicksson G, Friedman E.

Eur J Cancer. 2000 May;36(8):983-6.

PMID:
10885601
19.

Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel.

Rennert G, Dishon S, Rennert HS, Fares F.

Eur J Cancer Prev. 2005 Aug;14(4):357-61.

PMID:
16030426
20.

Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.

Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE.

Gynecol Oncol. 2001 Nov;83(2):383-7.

PMID:
11606101

Supplemental Content

Support Center